DARE Earnings

Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025

Published August 07, 2025 at 12:00 PM

SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company with a sole focus of closing the gap in women’s health between promising science and real solutions, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, August 14, 2025, to review its financial results for the quarter ended June 30, 2025 and to provide a company update.

Related Questions

What is the analyst consensus following the release, and how are major institutions altering their positions? How did management’s commentary address competitive threats and market share trends in the women’s‑health biopharma space? Did the earnings call reveal any changes to the shareholder return policy (dividends, share buybacks, or stock‑based compensation)? How did the company’s operating expenses and R&D spend change versus the prior quarter and the same quarter last year? Did the company announce any new product milestones or regulatory updates that could affect future sales? How did the Q2 2025 revenue and earnings per share compare to Wall Street consensus estimates? How does the current cash balance and runway compare to the company’s stated runway and financing needs? What guidance is management providing for Q3 and full‑year 2025 revenue, EPS, and cash flow? What is the status of any debt or convertible securities, and are there any upcoming maturities or refinancing plans? What were the key drivers of any revenue growth or decline (e.g., product launches, licensing deals, and geographic performance)? What were the latest updates on the company’s pipeline in women’s health, and how might they affect long‑term valuation? Are there any upcoming catalysts (e.g., IND filings, Phase III trial readouts, or partnership announcements) that could move the stock?